1.   首頁  
  2. |
  3.   產品專區  
  4. |
  5.   加值服務  
  6. |
  7.   客戶服務  
  8. |
  9.   企業專區  
  10. |
  11.   網路商城  
 
跨平台產品
Dr.eye PLUS
Dr.eye Quiz
 
家用産品
Dr.eye 365
Dr.eye 譯典通 X
Dr.eye 譯典通 X 升級版
 
行動産品
Dr.eye 雲端免費版
Dr.eye 雲端版 - 日語通
Dr.eye 雲端版 - 韓語通
Dr.eye Mobile for Android
Dr.eye Mobile for iPhone
 
硬體産品
Dr.eye 翻譯小子 X
Dr.eye 翻譯小子 3
 
過往產品
Dr.eye 譯典通 9.0 旗艦版
Dr.eye 譯典通 9.0 旗艦升級版
Dr.eye 譯典通 9.0 全民版
 
 

Licensing agreement brings Taiwan-developed pet medicine to US, Canada, NZ, and Australia


台灣開發的寵物藥物授權帶到美國,加拿大,紐西蘭和澳洲


Landmark agreement marks Taiwan’s entrance to western veterinary medical market


TAIPEI (Taiwan News) — The Taiwan-based drug development company, Lumosa Therapeutics, announced yesterday on their website that a licensing agreement with Skyline Vet Pharma (SVP), an American animal health product development company, has been signed for an animal pain management drug to enter specified western markets.

The new drug is "an extended-release analgesic injection for pain management in companion animals," according to the Lumosa website. The new drug is a combination of nabuphine, a kappa-agonist, and partial mu-agonist aimed at relieving moderate to severe pain in cats and dogs as well as other pets.


A deal is signed between Lumosa and SVP. (Photo: Lumosa website)

Under this agreement the drug, currently referred to as CS011 and soon to be SVP-161, will be further developed, commercialized, and marketed exclusively by SVP for resale in the United States, Canada, Australia, and New Zealand. SVP will continue the necessary animal clinical studies needed to fulfill all regulations.

Lumosa will receive a licensing fee, milestones payments, and royalties. At the time of signing, Lumosa received NT$200,000 (US$6,700) and anticipates around NT$800,000 after future payments.

Not only is this Lumosa’s first medicine to be authorized, CS011 will be the first medicine from Taiwan or China authorized for animal use in the United States, said UDN.

Lumosa specializes in developing drugs to treat neurological and inflammatory diseases. Lumosa products include Naldebain, a TFDA approved analgesic injection, and LT3001, a treatment for acute ischemic stroke.
 
Renee Salmonsen, Taiwan News, Staff Writer  
2018-01-17  

聯絡我們

客服專線 : (02)77378801
客服信箱 : service@dreye.com
服務時間 : 週一至週五 09:00~11:40 12:40~17:00 國定假日休息
購買鏈接
PC
Mobile
加入粉絲團


2017 Inventec Besta Co.,Ltd. All rights reserved
無敵科技股份有限公司版權所有
   隱私權聲明